国际标准期刊号: 2161-1165

Epidemiology: Open Access

开放获取

我们集团组织了 3000 多个全球系列会议 每年在美国、欧洲和美国举办的活动亚洲得到 1000 多个科学协会的支持 并出版了 700+ 开放获取期刊包含超过50000名知名人士、知名科学家担任编委会成员。

开放获取期刊获得更多读者和引用
700 种期刊 15,000,000 名读者 每份期刊 获得 25,000 多名读者

索引于
  • 哥白尼索引
  • 谷歌学术
  • 夏尔巴·罗密欧
  • Genamics 期刊搜索
  • 安全点亮
  • 访问全球在线农业研究 (AGORA)
  • 国际农业与生物科学中心 (CABI)
  • 参考搜索
  • 哈姆达大学
  • 亚利桑那州EBSCO
  • OCLC-世界猫
  • CABI 全文
  • 出租车直达
  • 普布隆斯
  • 日内瓦医学教育与研究基金会
  • 欧洲酒吧
  • ICMJE
分享此页面

抽象的

Evaluation of the Effectiveness of Risk Minimisation Measures Targeting Physicians on Prescribing Practices of Thiocolchicoside Containing Medicinal Products for Systemic Use

Laurence Sophie Jouaville, Carole Ehrhardt, Marie-Laure Kürzinger, Hanka de Voogd and Massoud Toussi

Introduction: In 2014, Risk Minimisation Measures (RMMs) concerning thiocolchicoside for systemic use were implemented in all European countries marketing the product. A Direct Healthcare Professional Communication (DHPC) and Educational Materials (EMs), were distributed to health care professionals to increase awareness related to genotoxicity risk.

Objectives: The objective of this study was to measure the effectiveness of RMMs, by ascertaining the proportion of targeted physicians who understood and implemented the latest prescribing conditions and safety information about systemic thiocolchicoside provided in the DHPC and EMs.

Methods: A cross-sectional web-based survey of prescribers of systemic thiocolchicoside was conducted in France, Greece, Italy and Portugal. Sampling targets for responding physicians were determined based on country specific prescribing patterns. Frequency of correct responses was calculated for six knowledge questions and information related to recent patients’ prescriptions of TCC was analysed.

Results: Among 651 responding physicians, 68.6% remembered having received either the DHPC or the EM or both. Knowledge was the highest for contraindications to the use of systemic thiocolchicoside, related to patients’ age (85.0%), pregnancy (87.6%), and lactation (80.3%) and was lower (49.1%) regarding restriction of use in women of childbearing potential not using contraception. Overall, knowledge of the right indication for use of systemic thiocolchicoside was 63.2%, while knowledge of dose and duration of treatment was higher for the oral form (78.9%) than for the injectable form (55.4%). These results were confirmed by the analysis of recent patients’ prescriptions. Knowledge varied by physician specialty and country and was higher for physicians who reported receiving either the DHPC or the EM or both.

Conclusion: This study reveals geographical as well as across prescribers’ specialty contrasts in the knowledge of key messages of systemic TCC containing medicinal products associated RMMs. In addition, the results showed that when risk minimisation materials (DHPC and EM) receipt was acknowledged by physicians, it improved their knowledge and attitude towards appropriate systemic TCC prescribing to patients.

免责声明: 此摘要通过人工智能工具翻译,尚未经过审核或验证。